Digestive and Liver Disease
Volume 42, Issue 4 , Pages 287-290 , April 2010

Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin

  • J.P. Gisbert

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
    • Corresponding Author InformationCorresponding author at: Playa de Mojácar 29, Urb. Bonanza, 28669 Boadilla del Monte, Madrid, Spain. Tel.: +34 915202254; fax: +34 913093911.
    • ,
  • A. Pérez-Aisa

      Affiliations

    • Gastroenterology Unit, Hospital Costa del Sol, Málaga, Spain
    • ,
  • M. Castro-Fernández

      Affiliations

    • Gastroenterology Unit, Hospital de Valme, Sevilla, Spain
    • ,
  • J. Barrio

      Affiliations

    • Gastroenterology Unit, Hospital Río Hortega, Valladolid, Spain
    • ,
  • L. Rodrigo

      Affiliations

    • Gastroenterology Unit, Hospital Central de Asturias, Oviedo, Spain
    • ,
  • A. Cosme

      Affiliations

    • Gastroenterology Unit, Hospital de Donostia and CIBEREHD, San Sebastián, Spain
    • ,
  • J.-L. Gisbert

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
    • ,
  • S. Marcos

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
    • ,
  • R. Moreno-Otero

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain

Received 24 February 2009 ,Accepted 10 June 2009.

References 

  1. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–781
  2. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825
  3. Gisbert JP, Calvet X, Gomollon F, et al. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc). 2005;125:301–316
  4. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ. 2000;320:31–34
  5. Axon AT. Treatment of Helicobacter pylori: an overview. Aliment Pharmacol Ther. 2000;14(Suppl. 3):1–6
  6. Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047–1057
  7. Gisbert JP, Pajares JM. Helicobacter pylori “rescue” therapy after failure of two eradication treatments. Helicobacter. 2005;10:363–372
  8. Gisbert JP, Gisbert JL, Marcos S, et al. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22:1041–1046
  9. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci. 2005;50:634–639
  10. Gisbert JP, Badia X, Roset M, et al. The TETRA study: a prospective evaluation of Helicobacter pylori ‘test-and-treat’ strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28–38
  11. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319–1328
  12. Gisbert JP, Maria Pajares J. Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review. Med Clin (Barc). 2001;116:111–116
  13. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs. 1999;57:905–920
  14. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16:315–324
  15. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–1384
  16. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol. 2001;1:7
  17. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005;10:157–171
  18. Houben MH, Van Der Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047–1055
  19. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68:535–565
  20. Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103:71–76
  21. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488–496
  22. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44
  23. Vaira D, Ricci C, Lanzini A, et al. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy. Dig Dis. 2007;25:203–205
  24. Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283–285
  25. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother. 2002;49:1039–1040
  26. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis. 2003;35:711–715
  27. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-Day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39–45
  28. Yahav J, Shmuely H, Niv Y, et al. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis. 2006;55:81–83
  29. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997–1002
  30. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22:45–49
  31. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821–825
  32. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339–1343
  33. Di Caro S, Assunta Zocco M, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 2002;14:1309–1312
  34. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, et al. Levofloxacin, amoxicillin and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2009;43(4):384–385
  35. Marzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006;11:237–242
  36. Rispo A, Di Girolamo E, Cozzolino A, et al. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter. 2007;12:364–365
  37. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769–2802

PII: S1590-8658(09)00255-2

doi: 10.1016/j.dld.2009.06.007

Digestive and Liver Disease
Volume 42, Issue 4 , Pages 287-290 , April 2010

Article Tools

* Image Usage & Resolution